Medipharm Labs Corp T.LABS

Alternate Symbol(s): MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.

TSX:LABS - Post by User

Medipharm Labs Corp > Lots of good gouge in this article.

<< Previous

Bullboard Posts

Next >>

Comment by QContinuum1on Aug 27, 2024 3:42pm

45 Views

Post# 36198234

RE:RE:RE:RE:RE:RE:RE:RE:RE:Lots of good gouge in this article.

Solid1 wrote: The ANDA filing can only be a 505(b)(2) filing, which is the equivalent of an NDA. That's how it's presented in the investor presentation. And Pidduck talked about the application and referred to it as an NDA. The active ingredients of Epidiolex cannot be patented. So if a new therapy is discovered, Epidiolex can be marketed as a new drug without infringing the patents. The new drug may only not be used to treat epilepsy, as this therapy is protected by patents.

ANDA = Epidiolex

Investigational NDA apparently = Keck trial

That is all.

<< Previous

Bullboard Posts

Next >>

BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient's Guide